Medicine
Oncology Couch: The Shadows of another Dimension
What children with cancer may be teaching us about medicine, uncertainty, and what it means to be human There are conversations in oncology that begin with a question. And then there are conversations in which, somewhere along the way, the…
From 10% to More Than 50% Survival: Tanzania Transforms Childhood Cancer Care, But Challenges Remain
In Tanzania in the early 2000s, healthcare for children with cancer was very limited. The majority of affected children never reached a treatment centre and 90% of those who did, ultimately died1. Today, childhood cancer care has been transformed with…
Behind Every Drug There Is a Story: Brian Druker, Imatinib, and the Human Journey Behind a Revolution in Cancer Care
Twenty-five years after imatinib transformed chronic myeloid leukaemia from a fatal diagnosis into a manageable disease for many patients, Brian Druker reflects on the curiosity, setbacks, and patients who shaped one of oncology's greatest breakthroughs. Long before I understood the…
Global Inequalities in Access to Radiation Treatment
Millions of cancer patients live within reach of life saving radiation treatment. Millions more live nowhere near it. The research maps just how wide, and how consequential, that gap has become. Radiotherapy is a cornerstone of modern cancer care. Around…
When RAS Becomes Treatable: Eileen O’Reilly on daraxonrasib in Pancreatic Cancer
Daraxonrasib nearly doubled median survival in previously treated metastatic pancreatic cancer. For Dr Eileen O’Reilly, the result is not simply a remarkable curve on a conference screen, but the beginning of a new way to think about a disease long…
Daraxonrasib: A Turning Point for Pancreatic Cancer
Pancreatic ductal adenocarcinoma remains one of the most difficult cancers to treat, with limited progress in drug development over the past decade. At the 2026 ASCO Annual Meeting, the Phase 3 RASolute 302 trial delivered results that stood out against…
Rewriting RAS: A New Targeted Option on the Horizon for Pancreatic Cancer
Metastatic pancreatic cancer remains one of the most treatment-refractory solid tumours in oncology. Despite multiple incremental refinements over the past decade, first-line therapy continues to rely on cytotoxic chemotherapy, most commonly FOLFIRINOX or gemcitabine plus nab-paclitaxel, with limited change in…
Immunotherapy’s Hidden Burden: Rethinking Toxicity in the Era of Breakthroughs
Immunotherapy has redefined cancer care—offering survival where little once existed, and in some cases, the possibility of long-term remission. But as its use expands across tumor types and earlier lines of treatment, a more complex reality is coming into focus:…
“Between the Checkpoints of Life, Take the Immunobuddies with You” —Professor Ricky Dylan Frazer
The conversation starts with a small detail that quickly becomes memorable. There is no coffee. On a podcast built around conversations over coffee, Professor Ricky Dylan Frazer, Consultant Medical Oncologist at Velindre Cancer Centre, Deputy CEO of the Immuno-Oncology Clinical…
Charles Balch Treated Thousands of Patients. He Says That’s Not His Greatest Work.
If you try to list everything Charles Balch has done, you quickly realize the list does not help you understand the man. He has led some of the most important institutions in oncology. He has built systems that are now…